Clinical trial
Arsenic Trioxide and Pamidronate in Treating Patients With Advanced Solid Tumors…
NCT00124605 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00124605 |
|---|---|
| Title | Arsenic Trioxide and Pamidronate in Treating Patients With Advanced Solid Tumors or Multiple Myeloma |
| Official title | Phase I Trial of Arsenic Trioxide in Combination With Pamidronate Disodium |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Refractory Multiple Myeloma, Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug, Other |
| Interventions | pamidronate disodium, arsenic trioxide, laboratory biomarker analysis, pharmacological study |
| Enrollment | 24 |
| Start date | Apr 1, 2005 |
| Primary completion | Jun 1, 2009 |
| First posted | Jul 28, 2005 |
| Last update posted | Jan 7, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: